1. Pink Sheet
  2. >>Legal & IP

Anatomy Of A Biotech Company: Acorda Gets Dressed For A Second Act

 
• By Brenda Sandburg

Acorda's rise, fall, and attempt to rise again is a snapshot of the life of a biotech. The company reached the commercial-stage pinnacle with Ampyra, only to eventually see it fall away to patent challenges. Now, after big staff cuts, the company is hoping to prevail in the commercial market again, this time with Inbrija.

Acorda Headquarters in Ardly NY

Two years ago, Acorda Therapeutics Inc. CEO Ron Cohen was sitting in the witness chair in the US District Court for the District of Delaware, trying to convince US District Judge Leonard Stark that the company's lead product Ampyra (dalfampridine) was a novel invention worthy of its patent protection.

Flash forward to today and the company has been through quite a re-invention. Acorda lost the patent infringement case and the first generic version of Ampyra – approved to improve walking in patients with multiple sclerosis –has entered the market, seven years earlier than expected

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.